HU 211-d6 is labelled HU-211 (H673505) which is a novel TNF-α inhibitor and an effective neuroprotectant. It might be a useful agent for the treatment of stroke patients, by protecting neuronal lysosomes from nitric oxide (NO)-mediated toxicity.
NMDA antagonist (IC 50 = 11 μ M for inhibition of [ 3 H]MK-801 binding to rat forebrain membranes). Protects against NMDA- and quisqualate-induced neurotoxicity (EC 50 = 3.8 μ M) and enhances dopamine D 1 receptor activity. Inhibits NF- κ B, reducing TNF- α , IL-6 and nitric oxide production, and acts as a free radical scavenger. Exhibits beneficial effects in experimental models of multiple sclerosis, bacterial meningitis, septic shock, epilepsy, and traumatic and ischemic brain injury. Brain penetrant.
[1]. eshhar n, striem s, biegon a. hu-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. neuroreport, 1993, 5(3): 237-240.
[2]. bar-joseph a, berkovitch y, adamchik j, et al. neuroprotective activity of hu-211, a novel nmda antagonist, in global ischemia in gerbils. mol chem neuropathol, 1994, 23(2-3): 125-135.
[3]. shohami e, novikov m, bass r. long-term effect of hu-211, a novel non-competitive nmda antagonist, on motor and memory functions after closed head injury in the rat. brain res, 1995, 674(1): 55-62.
[4]. gallily r, yamin a, waksmann y, et al. protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (hu-211), a nonpsychotropic cannabinoid. j pharmacol exp ther, 1997, 283(2): 918-924.
